Ibrutinib
Author:
Publisher
Springer Berlin Heidelberg
Link
http://link.springer.com/content/pdf/10.1007/978-3-642-54490-3_17
Reference36 articles.
1. Advani RH et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31(1):88–94
2. Bruton OC et al (1952) Absence of serum gamma globulins. AMA Am J Dis Child. 84(5):632–636
3. Burger JA et al (2012) The BTK inhibitor ibrutinib (PCI-32765) in combination with Rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia. In: Blood 120:Abstract 187
4. Burger JA (2013) Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 121(9):1501–1509
5. Byrd JC et al (2012) The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II Study. Blood 120:Abstract 189
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Folic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptor;Pharmaceutics;2023-04-07
2. Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer;World Journal of Clinical Cases;2022-09-26
3. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions;Cells;2022-04-14
4. Effects of tyrosine kinase inhibitors on androgen, estrogen α, glucocorticoid and thyroid receptors;Toxicology and Applied Pharmacology;2022-01
5. Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report;Skin Appendage Disorders;2019-10-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3